Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection.
Neutrophil elastase is present at high levels in airway fluid of patients with cystic fibrosis (CF), and is responsible for considerable inflammatory damage. Human monocyte/neutrophil elastase inhibitor (MNEI), a 42-kDa serpin protein, is an effective inhibitor of neutrophil elastase, cathepsin G, and proteinase-3, related proteases released from inflammatory neutrophils. We hypothesized that recombinant MNEI would reduce inflammatory damage and enhance bacterial clearance from the lung in an animal model of chronic Pseudomonas aeruginosa infection. In vitro studies showed that MNEI causes dose-dependent inhibition of the activity of rat neutrophil elastase. Recombinant MNEI was administered daily by aerosolization to rats previously inoculated with agar beads containing P. aeruginosa to initiate chronic infection. Administered MNEI was partially recovered in lavage fluid of treated rats as a 66-kDa complex with protease indicative of in vivo inhibition of elastase or a related protease. Aerosol treatment with MNEI significantly decreased the extent of inflammatory injury, quantified as the histopathology score. MNEI, which had no bactericidal effect on P. aeruginosa in vitro, significantly enhanced clearance of bacteria from infected rat lungs. The reduction of histopathology scores and enhancement of bacterial killing were evident 6 hr after a single aerosol treatment with MNEI. These findings indicate an important function of MNEI in protecting innate antimicrobial defense. Similar results were previously obtained for aerosolized prolastin (alpha1-antitrypsin), indicating that enhanced bacterial clearance by MNEI is due to inhibition of neutrophil protease. These findings demonstrate the value of this nonantibiotic protease inhibitor as an adjunct for the treatment and prevention of the infection component of CF lung disease.
Woods
Donald E
DE
Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Cantin
André
A
Cooley
Jessica
J
Kenney
Dianne M
DM
Remold-O'Donnell
Eileen
E
D000336:Aerosols / Q000008:administration & dosage*; D000818:Animals; D015153:Blotting, Western; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D002908:Chronic Disease; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D066298:In Vitro Techniques; D007958:Leukocyte Count; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D009504:Neutrophils / Q000201:enzymology / Q000473:pathology; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology; D011506:Proteins / Q000008:administration & dosage*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development* / Q000302:isolation & purification; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D015843:Serpins
D000336:Aerosols; D011506:Proteins; D011994:Recombinant Proteins; D015843:Serpins; C075177:SERPINB1 protein, human; D019272:Leukocyte Elastase